Table 1.
Plasma membrane transporters that have been evaluated for targeted drug delivery in the form of nanodevices.
| Transporter | HUGO Nomenclature | Target for Drug Delivery |
|---|---|---|
| ASCT2 | SLC1A5 | Tumors |
| GLUT1 | SLC2A1 | Blood–brain barrier Glioma |
| GLUT2 | SLC2A2 | Oral absorption |
| GLUT4 | SLC2A4 | Muscle, heart, adipocyte |
| SMVT | SLC5A6 | Oral absorption Tumors, Liver |
| ChT | SLC5A7 | Blood–brain barrier Glioma |
| ATB0,+ | SLC6A14 | Tumors |
| LAT1 | SLC7A5 | Blood–brain barrier Tumors |
| ASBT | SLC10A2 | Oral absorption |
| PepT1 | SLC15A1 | Oral absorption Ocular delivery Colitis |
| MCT1 | SLC16A1 | Oral absorption Blood–brain barrier |
| OCTN2 | SLC22A5 | Oral absorption Blood–brain barrier Glioma Ocular delivery |
| SVCT2 | SLC23A2 | Blood–brain barrier |